FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977173885> ?p ?o ?g. }

• W2977173885 endingPage "449" @default.
• W2977173885 startingPage "439" @default.
• W2977173885 abstract "Although patients with advanced-stage non-small cell lung cancers (NSCLC) harboring MET exon 14 skipping mutations (METex14) often benefit from MET tyrosine kinase inhibitor (TKI) treatment, clinical benefit is limited by primary and acquired drug resistance. The molecular basis for this resistance remains incompletely understood.Targeted sequencing analysis was performed on cell-free circulating tumor DNA obtained from 289 patients with advanced-stage METex14-mutated NSCLC.Prominent co-occurring RAS-MAPK pathway gene alterations (e.g., in KRAS, NF1) were detected in NSCLCs with METex14 skipping alterations as compared with EGFR-mutated NSCLCs. There was an association between decreased MET TKI treatment response and RAS-MAPK pathway co-occurring alterations. In a preclinical model expressing a canonical METex14 mutation, KRAS overexpression or NF1 downregulation hyperactivated MAPK signaling to promote MET TKI resistance. This resistance was overcome by cotreatment with crizotinib and the MEK inhibitor trametinib.Our study provides a genomic landscape of co-occurring alterations in advanced-stage METex14-mutated NSCLC and suggests a potential combination therapy strategy targeting MAPK pathway signaling to enhance clinical outcomes." @default.
• W2977173885 created "2019-10-03" @default.
• W2977173885 creator A5001552336 @default.
• W2977173885 creator A5003395713 @default.
• W2977173885 creator A5004509086 @default.
• W2977173885 creator A5005008854 @default.
• W2977173885 creator A5005862221 @default.
• W2977173885 creator A5007908496 @default.
• W2977173885 creator A5010032300 @default.
• W2977173885 creator A5014411546 @default.
• W2977173885 creator A5018948216 @default.
• W2977173885 creator A5019295794 @default.
• W2977173885 creator A5030510204 @default.
• W2977173885 creator A5033362539 @default.
• W2977173885 creator A5035793503 @default.
• W2977173885 creator A5036466135 @default.
• W2977173885 creator A5045554538 @default.
• W2977173885 creator A5048881344 @default.
• W2977173885 creator A5053320236 @default.
• W2977173885 creator A5059427266 @default.
• W2977173885 creator A5064071611 @default.
• W2977173885 creator A5070079018 @default.
• W2977173885 creator A5071273237 @default.
• W2977173885 creator A5077391276 @default.
• W2977173885 creator A5080860295 @default.
• W2977173885 creator A5082517668 @default.
• W2977173885 creator A5089311886 @default.
• W2977173885 date "2020-01-15" @default.
• W2977173885 modified "2023-10-14" @default.
• W2977173885 title "Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer" @default.
• W2977173885 cites W1969391810 @default.
• W2977173885 cites W1970527559 @default.
• W2977173885 cites W1995670055 @default.
• W2977173885 cites W2015616444 @default.
• W2977173885 cites W2021876472 @default.
• W2977173885 cites W2037873277 @default.
• W2977173885 cites W2044246917 @default.
• W2977173885 cites W2096540669 @default.
• W2977173885 cites W2098742726 @default.
• W2977173885 cites W2103110584 @default.
• W2977173885 cites W2106582614 @default.
• W2977173885 cites W2108861561 @default.
• W2977173885 cites W2111326065 @default.
• W2977173885 cites W2114843025 @default.
• W2977173885 cites W2117784514 @default.
• W2977173885 cites W2121993228 @default.
• W2977173885 cites W2149441684 @default.
• W2977173885 cites W2160212814 @default.
• W2977173885 cites W2169460814 @default.
• W2977173885 cites W2169624569 @default.
• W2977173885 cites W2180481128 @default.
• W2977173885 cites W2187358338 @default.
• W2977173885 cites W2205646851 @default.
• W2977173885 cites W2216675461 @default.
• W2977173885 cites W2230948985 @default.
• W2977173885 cites W2475363814 @default.
• W2977173885 cites W2521720507 @default.
• W2977173885 cites W2526076440 @default.
• W2977173885 cites W2559746652 @default.
• W2977173885 cites W2603411876 @default.
• W2977173885 cites W2614657635 @default.
• W2977173885 cites W2624310346 @default.
• W2977173885 cites W2625634490 @default.
• W2977173885 cites W2740079646 @default.
• W2977173885 cites W2740630940 @default.
• W2977173885 cites W2763698474 @default.
• W2977173885 cites W2766316939 @default.
• W2977173885 cites W2770026599 @default.
• W2977173885 cites W2770828094 @default.
• W2977173885 cites W2770833600 @default.
• W2977173885 cites W2794472180 @default.
• W2977173885 cites W2800224623 @default.
• W2977173885 cites W2805773873 @default.
• W2977173885 cites W2885387864 @default.
• W2977173885 cites W2898260831 @default.
• W2977173885 cites W2898789672 @default.
• W2977173885 cites W2947129619 @default.
• W2977173885 cites W2947852198 @default.
• W2977173885 cites W2947924247 @default.
• W2977173885 doi "https://doi.org/10.1158/1078-0432.ccr-19-1667" @default.
• W2977173885 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6980768" @default.
• W2977173885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31548343" @default.
• W2977173885 hasPublicationYear "2020" @default.
• W2977173885 type Work @default.
• W2977173885 sameAs 2977173885 @default.
• W2977173885 citedByCount "56" @default.
• W2977173885 countsByYear W29771738852020 @default.
• W2977173885 countsByYear W29771738852021 @default.
• W2977173885 countsByYear W29771738852022 @default.
• W2977173885 countsByYear W29771738852023 @default.
• W2977173885 crossrefType "journal-article" @default.
• W2977173885 hasAuthorship W2977173885A5001552336 @default.
• W2977173885 hasAuthorship W2977173885A5003395713 @default.
• W2977173885 hasAuthorship W2977173885A5004509086 @default.
• W2977173885 hasAuthorship W2977173885A5005008854 @default.
• W2977173885 hasAuthorship W2977173885A5005862221 @default.
• W2977173885 hasAuthorship W2977173885A5007908496 @default.
• W2977173885 hasAuthorship W2977173885A5010032300 @default.

• next